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Pharmacoeconomic evaluations are increasingly 
used in healthcare. By comparing costs and 
consequences of health interventions, economic 
evaluations can serve as a tool to help decision-
makers to efficiently allocate scarce resources. To 
conduct economic evaluations, researchers often 
obtain efficacy data from randomized controlled 
trials (RCTs). Although RCTs have, at least the-
oretically, high internal validity, they are associ-
ated with high levels of adherence compared with 
those observed in daily practice. The estimates of 
treatment efficacy and subsequently pharmaco-
economic results may therefore not be general-
izable to current community practice. In order 
to estimate the cost–effectiveness of the inter-
vention/drug in real-life settings, it is important 
that economic evaluations take adherence into 
account. Poor compliance and persistence will 
reduce the cost of the intervention, but at the 
same time might decrease the side effects and the 
therapeutic potential of drug therapy in terms of 
health effects and costs, and can therefore have 
a substantial impact on the  effectiveness and 
cost–effectiveness of drug therapies [1].
This study aims to highlight the impor-
tance of integrating medication adherence into 
pharmaco economic analyses, using osteoporosis 
as an example. Poor compliance and persis-
tence are common problems in the treatment 
of osteoporosis. Approximately 75% of women 
in whom an oral bisphosphonate – currently 
the most widely prescribed treatment for osteo-
porosis – is initiated have been shown to be non-
adherent within 1 year and 50% discontinued 
therapy by this time [2,3]. A few studies carried 
out to date have suggested important economic 
implications of poor adherence to osteoporosis 
medications [4–8].
More specifically, the purposes of this article 
are: first, to present and illustrate, by a published 
example including reviews and single studies, 
the impacts of poor adherence to osteoporosis 
medications on effectiveness, healthcare costs 
and cost–effectiveness; second, to review recent 
economic evaluations that have integrated com-
pliance and persistence; and last, to discuss some 
important challenges for incorporating compli-
ance and persistence into pharmacoeconomic 
analyses conducted in osteoporosis.
Definition & measurements
As a wide variety of definitions for medication 
adherence have been used in the literature, it 
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Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can 
reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, 
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with the definitions issued by an expert consensus group on osteo-
porosis [9], medication adherence is used as a general term to cover 
medication compliance and persistence. Medication compliance 
may be defined as “the extent to which a patient acts in accordance 
with the prescribed interval, dose and dosing of regimen” and 
medication persistence as “the length of time from initiation to 
discontinuation of therapy” [10].
Medication compliance is typically expressed as the percentage 
of prescribed doses taken in relation to the study period, often 
termed the medication possession ratio (MPR). Studies conducted 
on osteoporosis have estimated the mean MPR over a period of 
time (typically 1 year) and/or the probabilities of patients being 
highly or poorly compliant. A threshold of 80% has been most 
commonly used to define high compliance with osteoporosis 
treatments [11]. However, the definition of ‘good compliance’ is 
arbitrary and difficult to evaluate. An empirical calculation of an 
optimal threshold for predicting fracture risk has been estimated 
at 68% [12].
Persistence is measured as the number of days on therapy or 
as a dichotomous variable (persistent or not) as to whether a 
patient continued therapy beyond a certain elapsed time period 
(e.g., 12 months). A threshold regarding discontinuation period 
has to be defined for measuring persistence. For daily or weekly 
treatment, a refill gap of 1 month is commonly considered to 
define nonpersistence [13], but, as for MPR thresholds, there are 
no standardized definitions for nonpersistence. Gap lengths for 
treatments with longer dosing intervals are less well defined, 
although a working group recently discussed the notion that stop-
ping treatment for 2 months may be a suitable definition for a 
monthly treatment, and a delay of more than 3 months in the case 
of yearly injections [13]. The operational definitions to measure 
compliance and persistence could therefore differ between studies 
and may impact the results.
Medication compliance and persistence can be assessed using 
direct or indirect methods. Direct assessment methods (e.g., 
observation, serum drug concentration and biochemical ana lysis) 
are more accurate but are more costly and often impractical [14]. 
Indirect methods (e.g., retrospective prescription claims data-
base) often constitute the only available source to assess adherence 
and an inexpensive way of collecting adherence [15]. Most studies 
assessing medication adherence have used pharmacy prescription 
refill records. This method, however, lacks the details of daily dos-
ing (e.g., missing doses or wrong timing) and may underestimate 
medication nonadherence and, especially, noncompliance.
Impact of poor adherence on antifracture effectiveness
Poor adherence reduces the effectiveness of osteoporosis treat-
ment, resulting in lower bone mineral density gains and sub-
sequently higher fractures rates [16]. Two meta-analyses were 
recently performed to assess the fracture risk among patients who 
were noncompliant versus those who were compliant to ther-
apy for osteoporosis [17,18]. First, a meta-ana lysis of six articles, 
including 171,063 patients, suggested that the risk of fractures 
was 46% higher in noncompliant patients (MPR <80%) with 
bisphos phonate therapy compared with compliant patients [18]. 
The increased fracture risk in noncompliant patients was lower 
for nonvertebral (16%) and hip (28%) than for clinical verte-
bral fractures (43%). In another meta-ana lysis, encompassing 
113,376 patients from eight studies, of which the majority were 
retrospective database analyses considering the effect of adherence 
to bisphosphonate therapy, fracture risk increased by approxi-
mately 30% in noncompliant patients (MPR <80%) compared 
with compliant patients [17].
Most of these studies have suggested a nonlinear relationship 
between MPR and fracture risk [11]. For example, a large US data-
base showed no treatment benefit for compliance levels defined by 
an MPR <50% and then an exponential decrease of fractures rates 
as compliance increased [19]. Similarly, a German study observed 
no risk benefit with compliance levels of less than 60% [20]. 
Elsewhere, however, a linear relationship was observed between 
MPR (expressed as a continuous variable) and the probability of 
hip fractures [21]. Each incremental decrease of 1% in compliance 
resulted in an increase in the risk of hip fracture by 0.4% [21].
Nonpersistent patients also reported higher fracture rates 
compared with persistent patients. A meta-ana lysis including 
57,334 patients from five studies showed that nonpersistence 
increases the risk of all fractures by 30–40% versus persistence [18]. 
A recent Swedish observational study also showed that the 3-year 
fracture incidence was related to time on treatment with osteo-
porosis medications [22]. Consistent with RCTs, this study shows 
that, in real-life settings, at least 6 months of treatment with oral 
Figure 1. Impact of medication nonadherence on the 
clinical effectiveness (expressed as number of fractures 
prevented and quality-adjusted life-years gained) of oral 
bisphosphonates. Using a simulation model, this study 
estimated the lifetime effectiveness per patient at real-world 
adherence levels and full adherence with oral bisphosphonate 
compared with no treatment. Analysis was conducted in Belgian 
patients aged 55–85 years, either with a bone mineral density 
T-score ≤-2.5 or a prevalent vertebral fracture at baseline. 
Medication nonadherence decreased by 61 and 59% for the 
number of fractures prevented and the QALY gain of oral 
bisphosphonates compared with the full adherence scenario, 
respectively. 
QALY: Quality-adjusted life-year. 
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bisphosphonates can reduce fracture incidence [22,23]. No treat-
ment effect could therefore be assumed for patients receiving drug 
therapy for less than 6 months.
The magnitude of the effects of medication adherence should 
be interpreted with some caution [24]. A limitation to the obser-
vational studies is the concern surrounding bias due to the 
‘healthy adherer effect’, which could lead to an overestimation 
of medication benefits. While the reduced effectiveness observed 
in noncompliant and nonpersistent patients may be due to a true 
biological effect, it may also be at least partly caused by con-
founding factors due to differences between the types of patients 
who remain adherent versus those becoming nonadherent. In 
the Women’s Health Initiative’s study [24], adherence to placebo 
significantly reduced the risk of hip fracture by 50%. However, 
these results are not supported by another study that shows no 
evidence of healthy adherer bias in a frail cohort of seniors [25] 
and further exploration of the healthy adherer effect would be 
required in osteoporosis.
Acknowledging this potential limitation, poor adherence may 
be responsible for a large difference between efficacy and clini-
cal effectiveness. The consequences of poor adherence on the 
clinical effectiveness at a population level have been shown to be 
significant in many countries [4,6,7,26]. An example of the impact 
of medication adherence on effectiveness is provided in Figure 1. 
Using Belgian data on persistence and compliance to alendronate, 
an oral bisphosphonate [21], and simulation modeling [27], this 
study compared the clinical and economic outcomes obtained at 
real-world adherence levels with those expected with full adher-
ence over 3 years [4]. Outcomes were expressed as the number of 
hip fractures and in quality-adjusted life-years (QALYs), which is 
an attractive outcome measurement for cost–effectiveness analy-
ses that takes into account reductions in both morbidity and 
mortality. The numbers of hip fractures prevented were 0.0095 
and 0.0247 for the real-world and full adherence scenarios, 
respectively [4]. Therefore, the number of hip fractures prevented 
in the case of real-world adherence represents only 38.5% of 
that estimated with full adherence. The gain in QALYs in the 
real-world adherence scenario was estimated at 40.6% of that 
obtained under the full adherence scenario. More than half of the 
potential clinical benefits of oral bisphosphonates in patients with 
osteoporosis are therefore expected to be lost owing to poor com-
pliance and failure to persist with treatment. Sensitivity ana lysis 
has shown that the effect of nonadherence on clinical effective-
ness was primarily driven by issues of nonpersistence, with more 
than 90% of the clinical burden of poor adherence resulting from 
nonpersistence [4].
Impact of poor adherence on healthcare costs
Poor adherence will work in two opposite directions on health-
care resources [1]. Nonadherence reduces the cost of therapy but 
increases healthcare costs associated with the condition being 
treated as a result of reducing clinical effectiveness. The overall 
impact of nonadherence on healthcare costs will be primarily 
dependent on the risk of the population. The impact of poor 
adherence on therapy cost will be the same across different 
populations, but the number of fractures avoided and the corre-
sponding disease-related costs will increase as the fracture risk of 
the population increases. It could therefore be possible, in high-
risk populations, for the averted costs of treating the additional 
osteoporotic fractures resulting from noncompliance to exceed 
the cost of the additional therapy stemming from the improved 
compliance.
In our example including women between 55 and 85 years of 
age with either a bone mineral density T-score below -2.5 or a 
prevalent vertebral fracture, the full and the real-world adher-
ence scenarios had approximately the same total cost (Figure 2) 
[4], meaning that the additional costs from treating nonadherent 
patients to full adherence are approximately equal to the averted 
fracture costs resulting from improved adherence. Of course, 
the change in drug and nondrug costs is a function of both 
persistence and compliance [1,28].
Impact of poor adherence on cost–effectiveness
Given that compliance and persistence affect both health 
outcomes and costs, these concepts should be included to 
accurately estimate the cost–effectiveness of drug therapies. 
In our example using observational data (Figure 3), the impact 
of medication adherence on cost–effectiveness is substantial. 
The incremental cost per QALY gained of oral bisphospho-
nates compared with no treatment was estimated at €10,279 
and €3909 at real-world and full (assumed) adherence levels, 
respectively [4]. In this example, poor adherence therefore results 
Figure 2. Impact of medication nonadherence on 
aggregated and disaggregated (drug and disease) 
healthcare costs. Using a simulation model, this study estimated 
the aggregated and disaggregated costs associated with oral 
bisphosphonate therapy at real-world adherence and full 
adherence levels in comparison with no treatment. Analysis was 
conducted in Belgian patients aged 55–85 years either with a 
bone mineral density T-score ≤-2.5 or a prevalent vertebral 
fracture at baseline. Aggregated costs (total costs) include the 
costs of therapy (drug and monitoring costs) and fracture-related 
costs (disease costs).  
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in around a doubling of the cost–effectiveness from these medi-
cations. It means that for example, with a budget of €20,000, 
treatment with oral bisphos phonates could save 1.95 life-years 
in perfect health at real-world adherence levels while, at full 
adherence, treatment could preserve 5.12 life-years in perfect 
health. The studies addressing compliance and persistence have 
shown that both aspects of adherence were important drivers 
of cost–effectiveness [5].
Approaches to integrate nonpersistence & 
noncompliance into economic evaluations
In recent years, several studies have attempted to integrate medi-
cation compliance and/or persistence into pharmacoeconomic 
evaluations conducted in osteoporosis. As compliance and 
persistence are two different constructs, both concepts should 
ideally be separated. In order to avoid blurring the distinction 
between compliance and persistence, it is also important that 
compliance is defined in the subgroup of persistent patients. 
Studies generally provide assumptions with respect to persis-
tence but generally oversimplify the contribution of compli-
ance. Below, we describe some of the approaches to integrate 
persistence and compliance.
In the first economic models of persistence, including one by 
the National Institute for Health and Clinical Excellence in the 
UK, it was assumed that some patients completed the full 5-year 
course and the remaining (i.e., nonpersistent) patients received 
no treatment effect but 3 months of costs [29,30]. A value of 50% 
nonpersistent patients was selected in the base case. Patients who 
discontinue therapy early may have a marked impact on cost–
effectiveness, as they receive drug costs but have no treatment 
effect. For example, the incremental cost–effectiveness ratio of 
generic alendronate in UK women with bone mineral density 
T-scores equal to -2.5 and no prior fracture was estimated at 
GBP£3163, £3709 and £4914 per QALY gained when assum-
ing 30, 50 and 70% of nonpersistent patients, respectively [29]. 
However, in real-life settings, patients are likely to discontinue at 
any time and not only after 3 months [30].
More recent studies have therefore incorporated the possibil-
ity that patients can be at risk of discontinuation over the whole 
period of time [30–32]. Every patient is therefore considered to have 
a risk of stopping therapy in every cycle, based on observational 
adherence studies. For patients stopping therapy in each cycle, it 
is frequently assumed, first, that they receive no further treatment 
during the remaining modeling time and, second, that offset time 
(i.e., effect of treatment after stopping therapy) is similar to the 
duration of therapy. Although the latter notion seems reason-
able, assumptions made regarding the offset time may have a 
large impact on the results [30]. Limited data available from exten-
sion studies of RCTs have suggested that the discontinuation of 
oral bisphosphonate resulted in the gradual loss of its effects [33] 
and was found up to 7 years after treatment discontinuation [34]. 
Further research would, however, be needed to understand offset 
action of new anti-osteoporosis medications. The first assumption 
may be more critical as approximately a third of patients were 
shown to restart treatment within 6 months after discontinua-
tion [35,36]. How these patients change the cost–effectiveness is, 
however, unclear, and their inclusion in modeling may be difficult 
as the effectiveness of oral bisphosphonates used in an interrupted 
way is largely unknown.
Studies have also attempted to include medication compliance. 
Most studies assumed medication costs and fracture reduction 
efficacy to be proportional to compliance [27,37,38]. This approach 
may, however, be inappropriate since the relationship between 
MPR and fracture risk has been shown in most studies to be 
nonlinear [11].
Ström et al. used another approach to model compliance. They 
reduced treatment efficacy by a proportional factor of the optimal 
antifracture effect [30]. The authors suggested a 20% reduction of 
treatment benefit due to noncompliance in the base case, based 
on expert opinion. Noncompliant patients therefore deteriorated 
the cost–effectiveness because they received less benefit but had 
the same cost.
Hiligsmann et al. estimated the relative risks of fracture accord-
ing to MPR [5]. The effectiveness from clinical trials was applicable 
to the population with an MPR value equal to 80% and fracture 
reduction efficacy at other MPR values was estimated based on 
the relationship between compliance and fracture risk [19,21]. For 
generic oral bisphosphonates, the incremental cost–effectiveness 
ratio was estimated at €4871, £11,985 and €30,181 for 100, 80 
and 60% compliance, respectively.
Figure 3. Impact of medication nonadherence on the 
cost–effectiveness (expressed as cost in euros per quality-
adjusted life-year gained) of oral bisphosphonates 
compared with no treatment. This figure (called the ‘cost–
effectiveness plane’) presents the incremental effectiveness and 
costs of oral bisphosphonates compared with no treatment at 
real-world and full adherence levels. The incremental cost–
effectiveness ratio is represented by the slope of the line from 
the origin. The ana lysis was conducted in Belgian patients aged 
55–85 years either with a bone mineral density T-score ≤-2.5 or a 
prevalent vertebral fracture at baseline. 
QALY: Quality-adjusted life-year. 
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Hiligsmann et al. suggest an original 
methodology including real-world estimates 
for compliance with oral bisphos phonates 
[4,8,34]. Persistent patients were classified as 
compliant (MPR ≥80%) and poorly com-
pliant (MPR <80%). The probabilities of 
being compliant or not were derived for any 
given year and poorly compliant patients 
were assumed to be associated with an 
increased risk of fractures [21,39]. Drug costs 
were also related to the mean MPR of the 
patients.
Using this approach, the cost–effectiveness of denosumab com-
pared with generic alendronate (an oral bisphosphonate) was esti-
mated in the treatment of postmenopausal osteoporotic women 
[32], using real-world adherence data for alendronate and accepting 
an improved persistence for the 6-month subcutaneous injection 
of denosumab based on the results of an open-label study [40]. A 
shorter offset time of the antifracture effect after stopping treat-
ment was assumed for denosumab compared with that selected 
for alendronate. In the base-case ana lysis, the cost per QALY 
gained for denosumab compared with generic alendronate was 
estimated at €22,220 in women 70 years of age with bone mineral 
density T-scores of -2.5 or less. When assuming a 25% higher 
adherence for oral bisphosphonates, the incremental cost–effec-
tiveness ratio increased to €41,759. Medication adherence can 
therefore be considered as a key driver of the results. If adherence 
had not been included, the incremental cost–effectiveness ratio 
of denosumab compared with oral bisphosphonates would be 
less favorable. When comparing drugs with potential differences 
in medication compliance and persistence, the lack of inclusion 
of these concepts could bias the results and lead to suboptimal 
allocation of resources.
Economic value of adherence-enhancing interventions
In recent years, there has been an increasing interest in determining 
the effects of programs to improve adherence to osteoporosis medi-
cations. Several studies have investigated the effects of changing 
the dosing of regimens of bisphosphonates and/or improvements of 
compliance and persistence on the number of fractures prevented 
[6,41–44]. Some studies also estimated the economic value (in terms 
of cost per QALY gained) of improving medication compliance 
and persistence [26,30,45]. These studies did not assess the cost–effec-
tiveness of a specific program but estimated the cost–effectiveness 
of hypothetical interventions. As mentioned above, depending on 
the baseline risk for fractures, such interventions can, but will not 
necessarily be, cost effective.
Results of these studies suggest that interventions to improve 
adherence may likely confer cost–effectiveness benefits. So, 
for example, a hypothetical intervention with a one-time cost 
of US$250 and a reduction in discontinuation by 30% had an 
incremental cost per QALY gained of US$29,571 in American 
women aged 65 years starting bisphosphonates [26]. Other stud-
ies [4,31,46], reported in Table 1, estimated the maximum amount 
per year that would be cost effective to spend on interventions 
to improve medication adherence, depending on the level of 
improvement (between 10 and 50%).
Challenges for integrating compliance & persistence 
into pharmacoeconomic evaluations
Medication persistence and compliance are important drivers of 
cost–effectiveness analyses conducted in osteoporosis and should 
therefore be incorporated into pharmacoeconomic analyses. 
Measuring adherence and incorporating it into health economic 
modeling may, however, pose particular challenges. A number 
of avenues for further research have recently been identified [13]. 
First, it is probably necessary to have better (and standardized) 
definitions for compliance thresholds and for gap lengths for non-
persistence. This is particularly important for new osteo porotic 
treatments with different dosing regimens. Persistence data seem 
to be highly sensitive to gap length, which remains particularly 
uncertain for longer dosing regimens. Improvements in the 
measure ment of compliance and persistence are also required. 
The development and validation of tools to evaluate adherence 
(including missing doses and wrong timing) to osteoporosis 
medications would be useful [47]. Patient-related outcomes from 
validated questionnaires may provide robust complementary alter-
natives to medico-administrative database analyses, especially for 
compliance measurement.
Second, given the large difference between efficacy and effec-
tiveness, improvements in data collection, preferably in real-life 
settings, are expected. Using local and treatment-specific data are 
also important. Currently, the majority of studies have considered 
the effect of adherence to oral bisphosphonate therapies. Further 
work is expected to assess compliance and persistence with recent 
osteoporosis medications with longer dosing regimens. There is 
also a need to conduct studies to assess efficacy and effective ness 
according to types and levels of compliance. Retrieving efficacy 
data from RCTs for high compliance, as is currently frequently 
done, may be incorrect because compliance in the trials is not 
optimal for all patients. The efficacy from these trials is likely 
to be reduced to some degree because of noncompliance and 
nonpersistence. Therefore, using efficacy data from RCTs for 
high compliance probably underestimates the true underlying 
risk reduction with therapy. Clinical results should therefore also 
be related to the doses taken and not an assumed 100% persis-
tence and compliance [46]. Although compliance and persistence 
should be better reported in clinical trials, data on compliance and 
Table 1. Maximum cost per year for an adherence-enhancing 
intervention to be considered cost effective.
Adherence 
improvement (%)
Maximum cost per year
Sweden, 2009 [30]† Belgium, 2010 [4]‡ Ireland, 2012 [45]‡ 
10 €225 €73 €119
25 (30 for Sweden) €676 €149 €299
50 €1130 €239 €726
†Cost–effectiveness threshold of €60,000 per quality-adjusted life-year gained.
‡Cost–effectiveness threshold of €45,000 per quality-adjusted life-year gained.
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relation to effectiveness would ideally be derived from registers 
or observational studies. Additional insight into variables associ-
ated with noncompliance (such as age, first or second fracture, 
multimedication or comorbidity) would also be valuable. Many 
factors (such as the presence of comorbidities) are associated with 
medication adherence [48] and may therefore have an impact on 
the economic consequences of nonadherence. The effect of these 
factors should be further investigated.
Finally, in parallel with improvements in the collection of data, 
further work on methods to incorporate medication compliance 
and persistence into economic evaluations is also required. This 
should consider the inclusion of patients who restart therapy after 
discontinuation and better estimates of the true cost for compli-
ant and noncompliant patients. Using microsimulation models, 
it would also be possible to integrate the impact of events (such as 
prior fractures or treatment discontinuation) on compliance and 
persistence. Modeling compliance and persistence as continuous, 
rather than dichotomous, variables could also improve the power 
of the ana lysis. Performing sensitivity analyses on adherence data 
and assumptions is also recommended.
Expert commentary
A total of 10 years ago, Hughes et al. [49] and Cleemput et al. 
[50] reviewed the literature on the economic impact of noncom-
pliance and identified a need for more and better research. In 
2007 and 2009, Hughes et al. [1] and Rosen et al. [51], respec-
tively, provided updates of the reviews, suggesting that the 
work is still sparse, and that the limited evidence available has 
 methodological limitations.
In osteoporosis, the incorporation of medication compliance 
and persistence into pharmacoeconomic evaluations is relatively 
recent. Most studies recognize the importance of incorporating 
adherence into health economic models of osteoporosis [5,13,30]. 
Despite this, these concepts are not yet routinely included. 
Moreover, when adherence is included, a lack of methodological 
rigor and consistency in definitions may reduce the impact of 
medication non adherence. Few studies have included both persis-
tence and compliance aspects of treatment adherence. However, it 
should be noted that substantial improvements have been made in 
some recent studies. As discussed in this paper, the incorporation 
of medication compliance and persistence in pharmacoeconomic 
evaluations may be difficult and challenging, and also depends on 
data availability. Further research is required and should include 
the development of appropriate methodology and standards [1].
The importance of integrating medication compliance and 
persistence into pharmacoeconomic analyses is evident in osteo-
porosis, but also extends beyond this disease area. Previous stud-
ies have shown that noncompliance and nonpersistence have a 
substantial economic impact in patients with hypertension [52], 
diabetes mellitus [53,54] or renal transplantation [55]. Health eco-
nomic modelers should therefore consider the possible impact 
of nonadherence in all economic evaluations of drug or lifestyle 
interventions.
Five-year view
Medication compliance and persistence represents a new perspec-
tive in health technology assessment of osteoporosis [13]. It is our 
belief that, over the next 5 years, there will be an increase in the 
health economic papers incorporating medication compliance and 
persistence. This will be in line with the collection of additional 
adherence data. Moreover, as strategies to improve compliance and 
persistence may confer clinical and cost–effectiveness benefits, we 
would expect research on the effectiveness and cost–effectiveness 
of such programs.
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Key issues
• Medication noncompliance and nonpersistence reduce treatment effectiveness, impact on healthcare costs and may therefore alter the 
cost–effectiveness of drug therapies.
• Several studies carried out to date have suggested important economic implications of poor compliance and persistence with 
osteoporosis medications.
• Compliance and persistence should be an integral part of clinical (observational) studies and pharmacoeconomic analyses in order to 
estimate the cost–effectiveness of drug therapies in current community practice.
• Including adherence and incorporating it into health economic modeling may be challenging.
• Depending on their costs and effects, interventions to improve compliance and persistence with osteoporosis medications may confer 
cost-effective benefits.
• The cost–effectiveness of specific adherence-enhancing interventions should be explored.
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